The Impact of Psilocybin on Pain in Fibromyalgia Patients
A legfontosabb adatok
- Ki végzi
- Maastricht University
- Hol
- Leiden és Maastricht (Hollandia)Mind a 2 helyszín megnézése
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 35 fő, tervezett
- Kezdés
- 2024. máj. 3.
- Tervezett befejezés
- 2025. dec.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Psilocybin
- Hypnosis script
- A regiszteradat frissítve
- 2025. szeptember 15.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with fibromyalgia and moderate or stronger pain. It tests 2 low doses of psilocybin and a placebo on pain.
- Életkor
- 18 to 65 years
- Nem
- All sexes
- A betegség stádiuma
- Fibromyalgia diagnosed by the American College of Rheumatology criteria. Pain score of at least 5 out of 10. Body mass index between 18 and 28 kg/m2.
- Korábbi kezelés
- No regular use of psychotropic medicines such as opiates, antidepressants, muscle relaxants, anticonvulsants, sleep aids or benzodiazepines. One rescue painkiller is allowed, such as acetaminophen ≤4,000 mg/day, ibuprofen ≤1,200 mg/day, naproxen ≤660 mg/day, or ketoprofen ≤75 mg/day.
A részvétel fő kizáró okai
- Other painful conditions, such as inflammatory rheumatic diseases, migraines or headaches, or other medical conditions
- Current or past psychiatric conditions such as major depression, anxiety disorders or substance use disorder, or a psychotic disorder in a parent, sibling or child
- Past serious side effects from psychedelic drugs, such as anxiety or panic attacks
- Pregnancy, breastfeeding, or women not using reliable birth control
- High blood pressure (diastolic > 90 mmHg; systolic > 140 mmHg), past heart problems, smoking >20 per day or >20 alcoholic drinks per week
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Age between 18 and 65 years
- Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2
- Fulfilment of the American College of Rheumatology criteria for FM diagnosis (43)
- A minimum Numeric Rating Scale (numeric rating scale) pain score of 5 out of 10
- Proficient knowledge of the Dutch or English language
- Written Informed Consent
- Understanding the procedures and the risks associated with the study
- No regular use of psychotropic medication such as opiates, antidepressants, muscle relaxants, anticonvulsants, sleep aids, benzodiazepines. Non pharmacological regimens will be allowed along 1 rescue therapy such as acetaminophen ≤4,000 mg/day, ibuprofen ≤1,200 mg/day, naproxen ≤660 mg/day, or ketoprofen ≤75 mg/day. Use of paracetamol (PCM) and non-steroidal anti-inflammatory drugs (NSAIDS) will be allowed and monitored
- Willingness to refrain from taking psychoactive substances during the study
- Willingness to drink only alcohol-free liquids and no coffee, black or green tea, or energy drinks after midnight of the evening before the study session, as well as during the study days
- Willingness not to drive a traffic vehicle or to operate machines within 24 h after substance administration
Ki nem vehet részt
- Previous experience of serious side effects to psychedelic drugs (anxiety or panic attacks)
- Presence of any other painful condition such as inflammatory rheumatic diseases, migraines or headaches and of other chronic or acute medical conditions
- Presence or history of any other psychiatric condition such as primary major depressive disorder, anxiety disorders or substance use disorder as determined by the medical questionnaire, drug questionnaire and medical examination
- Psychotic disorder in first-degree relatives
- Hypertension (diastolic > 90 mmHg; systolic > 140 mmHg)
- History of cardiac dysfunctions (arrhythmia, ischemic heart disease…)
- Tobacco smoking (>20 per day)
- Excessive drinking (>20 alcoholic consumptions per week)
- Pregnancy or lactation
- For women: no use of a reliable contraceptive
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Helyszínek itt: Hollandia
- LUMCLeiden, HollandiaNo longer taking part
- Universiteit MaastrichtMaastricht, HollandiaNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
Rationale: Recent evidence shows that Lysergic Acid Diethylamide (LSD), even when administered in low, non-hallucinogenic doses, can produce analgesic effects and improve pain tolerance in a sample of healthy volunteers. Such results complement what was already observed with other serotonergic psychedelics such as psilocybin: survey studies and case series indicate that its use may lead to improvements in chronic pain conditions such as migraines, cluster headaches and phantom limb pain even at low, non-psychedelic doses. These effects have however not yet been investigated and confirmed in clinical populations under controlled experimental conditions.
A teljes eredeti leírásKevesebb
Fibromyalgia (FM) is a chronic condition characterised by widespread pain, hyperalgesia, anxiety, disturbed sleep patterns, impaired cognitive functioning and comorbid mood disorders. Most suggested therapies are only associated with small improvements in pain ratings and quality of life. Currently, there is no data concerning the effectiveness of serotonergic psychedelics in improving pain ratings in fibromyalgia patients.
Objective: The present study will explore the effects that the administration of a placebo and 2 low psilocybin doses (5 mg or 10 mg) will have on pain perception in a group of fibromyalgia patients.
Study design: The present study uses a double-blind, randomized, placebo-controlled design. All participants will receive a placebo and 2 doses of psilocybin (5 mg or 10 mg) and will undergo the Cold Pressor Test (CPT) and the Pain Pressure Threshold Task (PPT) o test its analgesic effects.
A vizsgálat csoportja
- Patient groupA vizsgált kezelés
Each participant will receive 2 different doses of psilocybin (5mg and 10mg) and a matching placebo on three separate occasions.
Kezelés: Psilocybin és Hypnosis script
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06368492: ki vehet részt
- A regiszteradat frissítve
- 2025. szeptember 15.